GSK GlaxoSmithKline Fundamental Research Analysis Report
(GSK) GlaxoSmithKline's current price is 48.17 US dollars, the medium-and long-term price trend (weekly K line MA10) is short, the weekly K line's current structure is down, the recent price trend (daily K line MA10) is short, and the daily K line's current form is down. The medium- to long-term price trend of the S&P 500 (weekly K-line MA10) is bullish. Strong operations, undervalued. The return on net assets of the core indicator was 12.77 in the current period, up 0.00 percent year-on-year. Core metrics Operating cash flow/net profit 1.60 for the period, 0.00 YoY. Core indicator price-earnings ratio PE current 13.22, nearly 10 years 29 points, 213.05 YoY, -0.06 month-on-month. The core indicator price-to-book ratio PB was 4.32 in the current period, up -17.25 YoY and -0.06 YoY. The core indicator, the federal funds rate, stands at 3.88 this period, placing it at the 71st percentile over the past 10 years, down 5.13% year-on-year and up 6.89% month-on-month.
Full report and figures: download the original Chinese file.
(GSK) GlaxoSmithKline's current price is 48.17 US dollars, the medium-and long-term price trend (weekly K line MA10) is short, the weekly K line's current structure is down, the recent price trend (daily K line MA10) is short, and the daily K line's current form is down. The medium- to long-term price trend of the S&P 500 (weekly K-line MA10) is bullish. Strong operations, undervalued. The return on net assets of the core indicator was 12.77 in the current period, up 0.00 percent year-on-year. Core metrics Operating cash flow/net profit 1.60 for the period, 0.00 YoY. Core indicator price-earnings ratio PE current 13.22, nearly 10 years 29 points, 213.05 YoY, -0.06 month-on-month. The core indicator price-to-book ratio PB was 4.32 in the current period, up -17.25 YoY and -0.06 YoY. The core indicator, the federal funds rate, stands at 3.88 this period, placing it at the 71st percentile over the past 10 years, down 5.13% year-on-year and up 6.89% month-on-month.